Clinical Trials Browser

Phase 2 × Renal Pelvic Carcinoma × tislelizumab × Clear all

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Phase 2 Recruiting

Renal Pelvic Carcinoma